‘Global Allergic Rhinitis Drugs Market Worth $13.9bn In 2021’ Says Visiongain Report

20 August 2018
Pharma

Visiongain’s new report Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines indicates that the global allergic rhinitis market will see $13.9bn in spending in 2021.

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021.
The lead analyst of the report said: “The global market for allergic rhinitis drugs was valued at $11.9bn in 2016. Oral antihistamines accounted for 39.9% of the total market in 2016. We expect this segment of the market to maintain its place as the leading segment within the market over the forecast period.
The rise of immunotherapy will be most noticeable in the US and Asia-Pacific markets during the forecast period, helping to meet increasing demand for allergic rhinitis treatments due to the expected global increase in the prevalence of allergic rhinitis. The allergic rhinitis drugs market will grow at a slow rate as initial declines in the oral antihistamine and intranasal corticosteroid segments are offset by growth in other areas, notably immunotherapy.”
The 255-page report contains 85 tables and 88 figures that add visual analysis in order to explain the developing trends within the Global Allergic Rhinitis Drugs Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.
This report also provides revenue forecast for 27 leading products in the allergic rhinitis drugs market.
The 255-page report offers market forecasts for the US, Germany, UK, France, Italy, Spain, China, Japan, India, Russia, Brazil and Rest of the World.

This report discusses the trends and development in the allergic rhinitis pipeline. Moreover, our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market.

The report Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines report will be of value to anyone who wants to better understand the allergic rhinitis drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the allergic rhinitis drugs market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever